Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takeru Shiroiwa

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
International Journal of Technology Assessment in Health Care|May 19, 2020
Cost-effectiveness evaluation for pricing medicines and devices: A new value-based price adjustment system in JapanTakeru Shiroiwa
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 29, 2013
[Economic evaluation of treatment on breast cancer]Takeru Shiroiwa
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2013
[Pharmacoeconomics of molecular target drug: K-ras testing and cetuximab for colorectal cancer as an example]Takeru Shiroiwa, Kiichiro Tsutani
Pharmacoeconomics|July 22, 2021
EQ-5D-Y Population Norms for Japanese Children and AdolescentsTakeru Shiroiwa, Takashi Fukuda
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 17, 2022
Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian ApproachesYasuhiro Hagiwara, Takeru Shiroiwa
Applied Health Economics and Health Policy|January 13, 2024
Are Web-Based Valuation Surveys for Preference-Based Measures as Reliable as Face-to-Face Surveys? TTO, DCE and DCE with DurationTakeru Shiroiwa, Takashi Fukuda
Molecular Diagnosis & Therapy|February 1, 2011
Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancerTakeru Shiroiwa, Yoshiharu Motoo, Kiichiro Tsutani
International Journal of Clinical Oncology|March 4, 2010
Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in JapanTakeru Shiroiwa, Takashi Fukuda, Kiichiro Tsutani
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 10, 2021
Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community SettingsTakeru Shiroiwa, Shinichi Noto, Takashi Fukuda
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 20, 2010
[Pharmacoeconomics of molecular target drugs in Japan]Kiichiro Tsutani, Ataru Igarashi, Takeru Shiroiwa
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
International Journal of Technology Assessment in Health Care|May 19, 2020
Cost-effectiveness evaluation for pricing medicines and devices: A new value-based price adjustment system in JapanTakeru Shiroiwa
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 29, 2013
[Economic evaluation of treatment on breast cancer]Takeru Shiroiwa
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2013
[Pharmacoeconomics of molecular target drug: K-ras testing and cetuximab for colorectal cancer as an example]Takeru Shiroiwa, Kiichiro Tsutani
Pharmacoeconomics|July 22, 2021
EQ-5D-Y Population Norms for Japanese Children and AdolescentsTakeru Shiroiwa, Takashi Fukuda
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 17, 2022
Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian ApproachesYasuhiro Hagiwara, Takeru Shiroiwa
Applied Health Economics and Health Policy|January 13, 2024
Are Web-Based Valuation Surveys for Preference-Based Measures as Reliable as Face-to-Face Surveys? TTO, DCE and DCE with DurationTakeru Shiroiwa, Takashi Fukuda
Molecular Diagnosis & Therapy|February 1, 2011
Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancerTakeru Shiroiwa, Yoshiharu Motoo, Kiichiro Tsutani
International Journal of Clinical Oncology|March 4, 2010
Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in JapanTakeru Shiroiwa, Takashi Fukuda, Kiichiro Tsutani
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 10, 2021
Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community SettingsTakeru Shiroiwa, Shinichi Noto, Takashi Fukuda
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 20, 2010
[Pharmacoeconomics of molecular target drugs in Japan]Kiichiro Tsutani, Ataru Igarashi, Takeru Shiroiwa
Pageof 7